China’s Sinovac Biotech will begin trialing its Covid-19 vaccine on children and adolescents in South Africa as part of a global study.
The firms said in a statement that the study will evaluate the efficacy, immunogenicity and safety of the Sinovac, CoronaVac, vaccine on children and adolescents aged 6 months to 17 years.
They said that the global trial will enroll 114 000 participants across Chile, the Philippines, Malaysia, Kenya and 2 000 in South Africa.
The trial has been approved by South African drugs regulator Sahpra and the first child will be vaccinated at the MeCRU Clinical Research Unit based at the Sefako Makgatho Health Sciences University on Friday (10 September 2021).
“The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac against confirmed symptomatic Covid-19 cases in children and adolescents. Efficacy will also be evaluated against hospitalisation and severe Covid-19,” Sinovac said.
South Africa has opened Covid-19 vaccinations to people over the age of 18 but currently does not accept children adolescents in its vaccine programme.
Follow FiND iT on Facebook here.